JPS6033089B2 - Method for separating precipitated proteins from albumin-containing suspensions - Google Patents
Method for separating precipitated proteins from albumin-containing suspensionsInfo
- Publication number
- JPS6033089B2 JPS6033089B2 JP51150986A JP15098676A JPS6033089B2 JP S6033089 B2 JPS6033089 B2 JP S6033089B2 JP 51150986 A JP51150986 A JP 51150986A JP 15098676 A JP15098676 A JP 15098676A JP S6033089 B2 JPS6033089 B2 JP S6033089B2
- Authority
- JP
- Japan
- Prior art keywords
- albumin
- filter
- filtration
- furnace
- mesh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 title claims description 37
- 102000009027 Albumins Human genes 0.000 title claims description 34
- 108010088751 Albumins Proteins 0.000 title claims description 34
- 239000000725 suspension Substances 0.000 title claims description 17
- 102000004169 proteins and genes Human genes 0.000 title claims description 15
- 108090000623 proteins and genes Proteins 0.000 title claims description 15
- 238000001914 filtration Methods 0.000 claims description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 102000006395 Globulins Human genes 0.000 claims description 8
- 108010044091 Globulins Proteins 0.000 claims description 8
- 238000000502 dialysis Methods 0.000 claims description 8
- 239000002002 slurry Substances 0.000 claims description 8
- 238000000926 separation method Methods 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 3
- 239000005909 Kieselgur Substances 0.000 claims description 3
- 239000003114 blood coagulation factor Substances 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 238000011010 flushing procedure Methods 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 238000007599 discharging Methods 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 229960005480 sodium caprylate Drugs 0.000 claims description 2
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 claims description 2
- 102000004506 Blood Proteins Human genes 0.000 claims 1
- 108010017384 Blood Proteins Proteins 0.000 claims 1
- 239000004744 fabric Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000002759 woven fabric Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 238000000665 Cohn process Methods 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- 241001062472 Stokellia anisodon Species 0.000 description 1
- 241001504592 Trachurus trachurus Species 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 239000010451 perlite Substances 0.000 description 1
- 235000019362 perlite Nutrition 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- FIWQZURFGYXCEO-UHFFFAOYSA-M sodium;decanoate Chemical compound [Na+].CCCCCCCCCC([O-])=O FIWQZURFGYXCEO-UHFFFAOYSA-M 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- External Artificial Organs (AREA)
Description
【発明の詳細な説明】
本発明は皿酸からアルブミンを回収して得られたァルブ
ミン含有懸濁液からの沈澱蛋白質の分離法に関する。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a method for separating precipitated proteins from an albumin-containing suspension obtained by recovering albumin from dish acid.
本発明の目的は袴願昭50−37713号記載の発明を
改良することである。血液、血液製品、アルプミン含有
体液
(戊d〆luid)等からアルブミンを回収する際、溶
解したアルブミンの他に沈澱蛋白質、特にグロプリンを
含むアルブミン含有懸濁液が得られる。The object of the present invention is to improve the invention described in Hakama Application No. 50-37713. When recovering albumin from blood, blood products, albumin-containing body fluids, etc., an albumin-containing suspension is obtained which, in addition to dissolved albumin, contains precipitated proteins, especially globulins.
これについて特顔昭50−37713号(西独公開特許
第241507y号)明細書は人間の血液等からアルプ
ミンを単離する方法を開示している。この方法は下記工
程からなっている。‘aー 血液(血液細胞及び血小板
)の固形成分から血数を分離し、更に必要あればこの血
酸から、溶解した非アルブミン成分を回収し、‘b}
分離した液を、組成がCH3−n(CH2)−OH(但
しnは0.1又は2)のアルコール及びカプリン酸ナト
リウムのようなアルブミン安定剤の存在下に約60〜7
500の温度に加熱することによりグロブリンを沈澱せ
しめ、ついでこの分泌液(nujd)を分離し、【cー
残余の分泌液に含まれるアルブミンを濃厚にする。Regarding this, the specification of Tokugan Sho 50-37713 (West German Published Patent Application No. 241507y) discloses a method for isolating albumin from human blood or the like. This method consists of the following steps. 'a - Separate the blood count from the solid components of blood (blood cells and platelets) and, if necessary, recover dissolved non-albumin components from this blood acid, 'b}
The separated liquid is heated in the presence of an alcohol having a composition of CH3-n(CH2)-OH (where n is 0.1 or 2) and an albumin stabilizer such as sodium caprate at a temperature of about 60 to 70%.
The globulins are precipitated by heating to a temperature of 500 °C, and this secretion (nujd) is then separated to enrich the albumin contained in the remaining secretion.
前記明細書に開示された方法は熱沈澱による沈澱グロブ
リン及び沈澱可能は蛋白質の分離を連続流中で遠心分離
するに際し約4.4のpHで行なっている。The process disclosed therein involves the separation of precipitated globulins and precipitable proteins by thermal precipitation at a pH of about 4.4 during centrifugation in continuous flow.
分離した蛋白質はローター内に集められるが、アルブミ
ンは上澄液中に残る。従来の分離法では比較的多量のア
ルプミンが分離された濃縮物中に残存するため、この有
用な残部アルブミンの回収に何回もの洗浄及び遠心分離
操作を繰返さなければならないのは不満足であると考え
られている。The separated proteins are collected in the rotor, but the albumin remains in the supernatant. In conventional separation methods, relatively large amounts of albumin remain in the separated concentrate, and we believe that it is unsatisfactory that multiple washing and centrifugation operations are required to recover this useful residual albumin. It is being
その上、遠心分離工程は非常に時間がかかるし、またき
わめて費用のかかる作業を伴なう。更に遠心分離機の雑
音は非常にうるさい。これらの欠点にも拘わらず、沈澱
グロブリン及び溶解グロブリンを含む懸濁物を遠心分離
工程により分離するために多年に亘つて行なわれている
コーン法に慣れ、また必要であったため池の操作法は何
ら考慮されていなかった。コーン法によって得られる懸
濁液は通常の条件下では炉週できないことが試験によっ
て示されている。これらの物質は前記明細書記載の方法
によって回収され、また従来のコーン法は同じ出発物質
から中間製品及び最終製品としての状態でほぼ同じ粘縄
度の物質が得られるという事実から、これ迄、これらの
方法で得られる物質が炉過できるとは全く考えられなか
った。Moreover, the centrifugation process is very time consuming and involves a very expensive operation. Furthermore, centrifuges are very noisy. Despite these shortcomings, we are familiar with the long-standing Cohn method for separating suspensions containing precipitated and lysed globulins by a centrifugation step, and the reservoir operation required Nothing was taken into account. Tests have shown that suspensions obtained by the Cohn process cannot be heated under normal conditions. These materials have been recovered by the method described in the above specification, and due to the fact that the conventional Kohn process yields materials of approximately the same viscosity in the intermediate and final product form from the same starting materials, It was never thought that the materials obtained by these methods could be filtered.
冷エタノール分別法で沈澱した蛋白質を除去するため種
々の炉適法が試みられている。経験によればこれらの沈
澱は恐らくその固有の粘糠度のため炉適法によって経済
的に除去することはできない。他の炉過法も検討されて
いるが、熱エタノールによる沈澱グロプリンの粘糠度は
冷エタノールによる沈澱グロブリンとはかなり異なって
いることが判った。以上の経験及び期待に反し、驚くべ
きことには本発明に従って懸濁液の扇状(alluvi
al)炉過により分離を行なえば、熱的に沈澱した蛋白
質を懸濁液から実質的に低コストで分離するという目的
が達成できる。Various furnace methods have been tried to remove proteins precipitated by cold ethanol fractionation. Experience has shown that these precipitates cannot be economically removed by furnace processes, probably because of their inherent consistency. Although other filtration methods have been investigated, it has been found that the consistency of globulin precipitated with hot ethanol is quite different from that of globulin precipitated with cold ethanol. Contrary to the above experience and expectations, surprisingly, according to the present invention, suspension
al) Separation by filtration achieves the objective of separating thermally precipitated proteins from suspensions at substantially lower costs.
扇状炉過自体は知られている。The fan furnace itself is known.
通常、扇状炉過は、中心の回転中空軸上に互いに並列し
て水平又は垂直に配置された環状フィルターェレメント
を有する密閉圧力容器を主体とする遠心精製フィルター
中で行なわれる。なおこれらのフィルターェレメントは
普通金属製撚り(ワイヤ一)又は編網織布を付けている
。炉過すべき物質は炉過助剤、通常珪藻土に添加混合す
る。Usually, fan filtration is carried out in a centrifugal purification filter mainly consisting of a closed pressure vessel having annular filter elements arranged horizontally or vertically in parallel with each other on a central rotating hollow shaft. These filter elements are usually made of metal strands (wire type) or knitted woven fabric. The material to be filtered is added to and mixed with a furnace filter aid, usually diatomaceous earth.
これら助剤は残澄のタイプ又は混濁度や性状に従って所
定の方法で添加する。フィルターェレメントに集められ
た炉液はフィル夕−ェレメントの回転及び向流フラツシ
ングにより炉別する。These auxiliaries are added in a predetermined manner depending on the type, turbidity and properties of the residual liquid. The furnace liquor collected in the filter element is separated by rotation of the filter element and countercurrent flushing.
残澄はいわゆるスラリーとして排出させる。他のタイプ
のフィルターや炉過法は時間のかかる遠心分離法以上の
利点が全く得られない程長い炉過時間を要するのに対し
、本例の扇状炉過は驚くべき利点を与える。The residual liquid is discharged as so-called slurry. While other types of filters and filtration methods require long filtration times that provide no advantage over the time-consuming centrifugation method, the present fan filtration provides surprising advantages.
ここでカーボン及びアスベスリト板フィルターによる精
製炉過、セルロースをベースとした炉過層、ガラス繊維
フィルター及び半融ガラスによる精製炉過法について試
験した結果を示す。これらの炉過法はいずれもフィル夕
−ェレメントの詰り又は炉液の濁りによって非常に長い
炉過時間を要した。これに対し扇状フィルターを使用し
ただけで透明な炉液を得ることができ、別の付加的清浄
又は精製炉週を要さず、従ってアルブミンを得るための
最適回収操作となり得る。詳しくは、この扇状炉過は密
閉容器を有し、且つフイルターエレメントのメッシュが
20〜200ミクロンの遠心精製フィルター中で行なう
ことを提案する。Here, we will show the results of tests on refining furnace filtration using carbon and asbestos plate filters, cellulose-based furnace filtration, glass fiber filters, and refining furnace filtration methods using smelt glass. All of these filtration methods required very long furnace times due to clogging of the filter element or turbidity of the furnace liquor. In contrast, the use of a fan filter alone allows obtaining a clear filtrate, without requiring a separate additional cleaning or purification process, and thus can be the optimal recovery operation for obtaining albumin. Specifically, it is proposed that this fan filtration be carried out in a centrifugal purification filter having a closed container and a filter element having a mesh of 20 to 200 microns.
更に詳しくは問題の液は70〜90ミクロンのメッシュ
で処理する。More specifically, the liquid in question is treated with a 70-90 micron mesh.
このメッシュサイズは得られる貫流(throughH
ow)を最適条件にし、完全な炉過を達成させることが
できる。この場合一回の炉過工程だけを各操作で行えば
よい。次の炉過のためにフィルター表面を充分使用可能
な状態に準備しておくには場合によりフィルターェレメ
ントを中性液プラィマーでプレコートした後、厚さ約0
.5肌に炉過助剤層でプレコートするのが得策である。This mesh size corresponds to the obtained throughflow (throughH
ow) can be set to the optimum condition and complete filtration can be achieved. In this case, only one furnace step needs to be carried out in each operation. To fully prepare the filter surface for the next filtration, the filter element may optionally be precoated with a neutral liquid primer to a thickness of approx.
.. 5 It is a good idea to pre-coat the skin with a layer of furnace additive.
炉過助剤としては一般に市販品として入手できる珪薮士
(商品名ハイフロースーパーセル、セラィトS45)又
は真珠岩が適当である。更に炉過効果は若干劣るが、セ
ルロース炉過助剤も有用である。これらの炉過助剤によ
り同様に多くの用途に対し満足すべき製品を得ることが
できる。炉過助剤は予め膨潤させるか或いは予め含浸さ
せておくことが好ましい。有利な炉過効果を得るには8
0ミクロンメッシュの金属製撚り(ワイヤ‐)又は編網
織布の、水平に配置したフィルターェレメントがよい。As the furnace auxiliary agent, Keibushi (trade name: High Flow Super Cell, Celite S45) or Perlite, which are generally available as commercial products, are suitable. Furthermore, cellulose filtering aids are also useful, although the filtering effect is slightly inferior. These furnace aids likewise make it possible to obtain satisfactory products for many applications. It is preferable to swell or impregnate the furnace auxiliary agent in advance. 8 to obtain advantageous filtering effect
Horizontal filter elements of 0 micron mesh metal wire or knitted woven fabric are preferred.
好ましい組成物は約4〜6%の血鰍蛋白質の懸濁液であ
って、これに1〆当り20〜70夕の珪藻±炉週助剤を
添加する。A preferred composition is a suspension of about 4-6% hemiplast protein to which is added 20-70 g of diatom + furnace additive per batch.
ついでこの懸濁液を炉過する。蛋白質の濃度が低い時は
ある環境下では炉過助剤の量は少なくてよい。またスラ
リー或いは混濁分の中に存在するアルブミンを回収する
には、回転及び向流フラツシングにより清掃するか、又
は再循環システムで残分炉過装置の所の残分を清掃後、
全フィルター面積の一小部を占める残分炉過装置によっ
て同様にこのアルブミンを単離することを提案する。This suspension is then filtered. Under certain circumstances, when the protein concentration is low, the amount of furnace aid may be reduced. Albumin present in the slurry or turbidity can also be recovered by cleaning by rotation and countercurrent flushing, or by cleaning the residue at the residue filter with a recirculation system.
It is proposed to isolate this albumin as well by means of a residue filtration device which occupies a small portion of the total filter area.
収量を増加させるには、炉過容量を低下させずに4.0
〜2.5ゞール(気圧)でこの方法を行なうことができ
る。4.0 to increase yield without reducing furnace overcapacity.
This process can be carried out at ~2.5 gallons (atmospheric pressure).
以下、本発明を実施例によって詳細に説明する。Hereinafter, the present invention will be explained in detail with reference to Examples.
次の2例は2つの異なった懸濁液を原料としている。実
施例1は特顔昭50一37713号明細書に記載の方法
で作られた懸濁液を用いたものである。実施例
人間の血液から固形分(血液細胞及び血小板)を分離し
て凝固因子を除く。The following two examples are based on two different suspensions. Example 1 uses a suspension prepared by the method described in Tokugan Sho 50-137713. Example Solid matter (blood cells and platelets) is separated from human blood to remove clotting factors.
この出発溶液は約5〜6%の血※蛋白質を含有する。前
記明細書に開示された方法に従って、凝固因子第肌及び
フィブリノーゲンを冷エタノール沈澱法によって除去す
る。原皿酸は肝炎(Hepatitis)活性がマイナ
スで、通常のトランスアミナーゼ値を有し、また可視的
なヘモグロビンを全く含まないものである。この原血鰍
に濃度が0.004モルになる迄、アルフミン安定剤と
してカプリル酸ナトリウムを加える。この混合物はエタ
ノールを約9%(容量)含むが、これをPH6.5で加
熱する。PH値は0.州‐HCIで調節する。次に温度
を約3時間かけて粥℃に高めた後、液を10qoに冷却
する。更にこの懸濁液を冷却し、10q○の温度で加工
する。加工を行なった溶液はアルブミンを約2〜2.5
%含有する。添付図面に出発溶液の加工を図示的に示す
。この方法では最大5時間の炉過時間内で600その血
数分離を行なうための変形回転排出フィルター(タイプ
ZHF−S、シェンク縦型)を用いた。この完成システ
ムの中央部の装置は加熱及び冷却の両処理が可能な2重
壁を有し、約3あの炉過表面積を有する容量約220そ
のフィルター容器20である。環状のフィルター円板2
2を、炉液が各円板を覆うフィルター媒体をいったん通
ってから中央塔21に、ついでライン23及びバルブ8
を通って出口に流入するように中央回転塔21に取付け
る。炉過サイクル中の残澄(炉過助剤及び沈澱したグロ
ブリン)は遠心分離による洗浄及び1%NaCIの還流
洗浄によって除去する。その結果、フィルターは次のサ
イクルに容易に使えるようになる。フィルターェレメン
トは金属製撚り(ワイヤ‐)又は編網織布を覆ったもの
である。禾炉週の出発溶液は一様に鍵梓(雛梓機3)さ
れているスラリータンク24内の懸濁液中に維持されて
いる。This starting solution contains approximately 5-6% blood* protein. According to the method disclosed in said specification, clotting factors and fibrinogen are removed by cold ethanol precipitation. The raw acid has negative Hepatitis activity, normal transaminase values, and no visible hemoglobin. Sodium caprylate is added as an albumin stabilizer to this raw blood mackerel until the concentration becomes 0.004 mol. This mixture, which contains approximately 9% (by volume) ethanol, is heated to a pH of 6.5. PH value is 0. State-Adjusted by HCI. The temperature is then raised to porridge C over about 3 hours, and then the liquid is cooled to 10 qo. This suspension is further cooled and processed at a temperature of 10q○. The processed solution has an albumin content of approximately 2 to 2.5
%contains. The processing of the starting solution is shown diagrammatically in the accompanying drawings. In this method, a modified rotary discharge filter (type ZHF-S, Schenck vertical type) was used to perform 600 blood count separations within a maximum furnace time of 5 hours. The central device of the complete system is a double-walled filter vessel 20 capable of both heating and cooling, with a capacity of approximately 220 mm and a furnace surface area of approximately 3 mm. Annular filter disk 2
2, once the furnace liquid has passed through the filter media covering each disk, to the central column 21, then to line 23 and valve 8.
It is attached to the central rotating tower 21 so that it flows through the outlet to the outlet. Residue from the filtration cycle (furnace aid and precipitated globulin) is removed by centrifugal washing and 1% NaCI reflux washing. As a result, the filter can be easily used for the next cycle. The filter elements are covered with metal strands (wires) or knitted woven fabrics. The raw starting solution is maintained in suspension in a slurry tank 24 which is uniformly sealed.
この出発物質はスラリー供総合バルフ10を通して1対
の入口バルブ11,12からフィルター容器2川こ入れ
る。この容器は圧縮空気バルブ5からの圧縮空気により
加圧する。まず、フィルターェレメソトを500机上の
蒸留水にセラィト私5(珪藻土炉過助剤の商品名)約1
000ポンドを懸濁した懸濁液中の蒸留水及び炉過助剤
でプレコートして大気圧において厚さ約0.2伽のプラ
ィマープレコートを形成させる。The starting material enters two filter vessels through a slurry valve 10 and a pair of inlet valves 11,12. This container is pressurized with compressed air from compressed air valve 5. First, add 500ml of filter elemesoto to distilled water on a desk and add about 15% of Celite (trade name of diatomaceous earth furnace super-aid).
000 lbs. in suspension with distilled water and furnace aid to form a primer precoat approximately 0.2 mm thick at atmospheric pressure.
ついでこの混合物をスラリータンクからフィルター容器
に入れ、2バール(気圧)の正圧でェレメント22の炉
過表面を通過させる。清浄なタンクにこの液体を実際に
配合する前に、炉液が透しガラス25で充分透明になる
までいわゆる再循環プロセス(再循環バルブ6、ポンプ
2)でくり返しフィルターヱレメントに前記物質を通す
。フィルターから透明なアルブミン含有溶液がなくなる
と同時に1%NaCIの洗浄溶液をポンプでフィルター
に通す(使用する洗浄溶液の量は元のバッチサイズの容
量の半分である)。The mixture is then transferred from the slurry tank into a filter vessel and passed through the furnace surface of element 22 at a positive pressure of 2 bar. Before actually dispensing this liquid in a clean tank, the substance is passed through the filter element repeatedly in a so-called recirculation process (recirculation valve 6, pump 2) until the furnace liquid is sufficiently transparent through the see-through glass 25. . A wash solution of 1% NaCI is pumped through the filter as soon as the filter is free of clear albumin-containing solution (the amount of wash solution used is half the volume of the original batch size).
炉過速度は150夕/hrである。この方法の初期にお
ける炉液中の蛋白質濃度は約2.5%であり、一方、非
アルフミン成分の最終濃度は約0.05%に過ぎない。
得られた溶液は透明で、約1.5%のァルブミン蛋白質
濃度及び約100仇hosmの鯵透度(osmolat
ity)を有する。次にこの透明炉液をミリポアベリコ
ンカセットシステム(西独ノィアィゼンブルク、ミリポ
ア社製、炉☆表面積9.0の)を用いて透析炉過する。Furnace overspeed is 150 evening/hr. The protein concentration in the furnace fluid at the beginning of the process is about 2.5%, while the final concentration of non-alhumic components is only about 0.05%.
The resulting solution was clear, with an albumin protein concentration of about 1.5% and an osmolarity of about 100 hosm.
ity). The transparent solution was then filtered through a dialysis furnace using a Millipore Vericon cassette system (manufactured by Millipore, Neuesenburg, West Germany, furnace surface area: 9.0).
透析炉週とは溶液を透析膜を通して炉過することをいう
。この方法における初期の流速は約5〜6そ炉液/分で
ある。Dialysis refers to filtering a solution through a dialysis membrane. The initial flow rate in this process is about 5-6 mol/min.
1日につき8時間交代に操業すると分別の全工程は3日
かかる。The entire separation process takes three days when operating in eight-hour shifts per day.
第1日:熱エタノールによる沈澱、引続き冷却及びPH
4.4に調整(5時間)。Day 1: Precipitation with hot ethanol, followed by cooling and pH
Adjusted to 4.4 (5 hours).
第2日:扇状炉週(4時間)及び透析炉週(流速はプロ
セスが第3作業日の初めに終るように調整)。Day 2: Fan oven week (4 hours) and dialysis oven week (flow rate adjusted so that the process ends at the beginning of the third working day).
原料は両工程とも2重壁の容器を冷却することにより十
60〜十8℃の温度に維持する。第3日:pH(7.0
)、蛋白質濃度(5%、20%)、鯵透度(30仇ho
sm)の最終調整;透明炉過;滅菌炉過(膜0.2ム)
;ビン詰め;加熱殺菌(1畑時間、60℃)。In both steps, the raw material is maintained at a temperature of 160-18° C. by cooling in double-walled containers. 3rd day: pH (7.0
), protein concentration (5%, 20%), horse mackerel transparency (30℃)
final adjustment of sm); transparent oven filtration; sterilization oven filtration (membrane 0.2 μm)
; Bottling; Heat sterilization (1 field hour, 60°C).
扇状炉過/透析炉過工程を用いた時のァルブミンの収量
は元の出発原料中に存在するアルプミンの鎌%(6ルゞ
ッチの平均)で、また最終製品の品質は以前の方法で行
った場合のものと同様であったが、この方法の最大の利
点はビン詰めを除き1人で全工程を行ない得ることであ
る。The yield of albumin when using the fan filtration/dialysis filtration process is the sickle percent of albumin present in the original starting material (average of 6 lugches), and the quality of the final product is the same as that of the previous method. The biggest advantage of this method is that one person can do all the steps except for bottling.
フィルターの清掃は駆動モーター1でフィルターェレメ
ントを回転させ、ついでスラリーを排出バルブ9から排
出させて行なう。The filter is cleaned by rotating the filter element with the drive motor 1 and then discharging the slurry through the discharge valve 9.
バルブ4を通って排出された物質は再び懸濁させ炉過す
ることができる。フィルター通過後の液体はもはやチン
ダル効果を示さず、水のように透明である。The material discharged through valve 4 can be resuspended and filtered. The liquid after passing through the filter no longer shows the Tyndall effect and is clear like water.
この液は他の蛋白質脂質等の同伴物質を含まない。この
液は直接アルブミンの飽和に用い、次の炉週万法(特鹿
昭50一37713号参照)を行なうことができる。こ
の方法は原理的に下記工程を受ける。血酸
600k9:3.6k9の蛋白質
18.48k9のアルブミン(:55%)・十9%エタ
ノール
十0.004モルのカブリル酸ナトリウム十日CI p
H6.5
2 熱沈澱:3び分、68q○
3 十HC1 pH4.4
4 扇状炉過
炉液
5 透析炉過
5.1 濃縮
5.2 透析
6 NaOH pH7.0
7 透明炉週
アルブミン溶液
17.2k9アルブミン(=93%収量)This liquid does not contain accompanying substances such as other proteins and lipids. This liquid can be used directly to saturate albumin and perform the following Furashimanpo method (see Tokuka Sho 50-137713). This method basically involves the following steps. Blood acid 600k9: 3.6k9 protein 18.48k9 albumin (:55%) 19% ethanol 10.004 mol sodium cabrylate 10 days CI p
H6.5 2 Thermal precipitation: 3 minutes, 68q○ 3 10HC1 pH 4.4 4 Fan furnace filter solution 5 Dialysis furnace filter 5.1 Concentration 5.2 Dialysis 6 NaOH pH 7.0 7 Transparent furnace weekly albumin solution 17. 2k9 albumin (=93% yield)
図は本発明方法に用いられる扇状炉過装置の一例である
。
1……モーター、2……ポンプ、3……雛梓機、4,5
,6,8,11,12・・・・・・バルブ、20・・・
・・・フィルター容器、21・・・・・・中央塔又は回
転塔、22……フィルター円板、23……ライン、24
……スラリータンク、25……透しガラス。The figure shows an example of a fan filtration device used in the method of the present invention. 1... Motor, 2... Pump, 3... Hinazusa machine, 4,5
, 6, 8, 11, 12... Valve, 20...
... Filter container, 21 ... Central tower or rotating tower, 22 ... Filter disk, 23 ... Line, 24
...Slurry tank, 25...Transparent glass.
Claims (1)
容量%のアルコール及びアルブミン安定剤としてカプリ
ル酸ナトリウムの存在下に約60〜75℃の温度で熱処
理し、ついで冷却後、pHを約4に低下せしめて主とし
てグロブリンからなる非アルブミン成分を沈澱せしめ、
ついでこうして得られたアルブミン含有懸濁液を織布製
フイルターエレメントで扇状濾過することによりフイル
ターエレメント上に非アルブミン成分を集めると共に、
濾過製品として透明なアルブミン溶液を得ることを特徴
とするアルブミン含有懸濁液からの沈澱蛋白質の分離法
。 2 前記濾過を密閉圧力容器を有する、メツシユが20
〜200ミクロンの遠心精製フイルター内で行なう特許
請求の範囲第1項記載の方法。 3 前記フイルターエレメントの一つが70〜90ミク
ロンのメツシユを有する特許請求の範囲第2項記載の方
法。 4 前記濾過をメツシユが80ミクロンの金属製撚り(
ワイヤー)又は編網織布を有する水平に配置されたフイ
ルターエレメントで行う特許請求の範囲第2項記載の方
法。 5 約4〜6%の血漿蛋白質の懸濁液を1l当り約30
〜70gの珪藻土濾過助剤と混合する特許請求の範囲第
1及び第4項記載の方法。 6 セルロース濾過助剤を予め膨張又は含浸した状態で
使用する特許請求の範囲第1項及び第5項記載の方法。 7 回転及び向流フラツシングにより清掃した後又は再
循環プロセスにおいて残分濾過装置の内容物を清掃した
後、残分濾過装置によるプレコート組成物に含まれるス
ラリー又は混濁物を排出する特許請求の範囲第1項、第
2項及び第6項記載の方法。8 前記方法を4.0±2
.5パール(気圧)の正の濾過圧で行なう特許請求の範
囲第2項及び第6項記載の方法。 9 透明なアルブミン溶液を(透析膜により)透析濾過
する特許請求の範囲第1項記載の方法。[Claims] 1. Plasma from which coagulation factors have been separated is heated to about 9% at approximately neutral pH.
% by volume of alcohol and sodium caprylate as an albumin stabilizer at a temperature of about 60-75°C and then, after cooling, lowering the pH to about 4 to precipitate non-albumin components consisting primarily of globulins;
The albumin-containing suspension thus obtained is then fan-filtered through a woven filter element to collect non-albumin components on the filter element.
A method for the separation of precipitated proteins from albumin-containing suspensions, characterized in that a clear albumin solution is obtained as a filtered product. 2 The mesh having a sealed pressure vessel for the filtration is 20
The method according to claim 1, which is carried out in a centrifugal purification filter of ~200 microns. 3. The method of claim 2, wherein one of said filter elements has a mesh of 70 to 90 microns. 4 The filtration mesh is made of 80 micron metal strands (
3. The method as claimed in claim 2, wherein the method is carried out with horizontally arranged filter elements having a wire or a knitted fabric. 5 Approximately 4-6% plasma protein suspension at approximately 30% per liter
5. The method of claims 1 and 4, wherein the method is mixed with ~70g of diatomaceous earth filter aid. 6. The method according to claims 1 and 5, wherein the cellulose filter aid is used in a previously expanded or impregnated state. 7 Discharging the slurry or turbidity contained in the precoat composition through the residue filtration device after cleaning by rotation and countercurrent flushing or after cleaning the contents of the residue filtration device in a recirculation process The method described in Items 1, 2 and 6. 8 The above method was 4.0±2
.. A method according to claims 2 and 6, which is carried out at a positive filtration pressure of 5 par (atmospheres). 9. The method according to claim 1, wherein the transparent albumin solution is diafiltered (through a dialysis membrane).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2556733.3 | 1975-12-17 | ||
| DE2556733A DE2556733C3 (en) | 1975-12-17 | 1975-12-17 | Method for isolating albumin from blood plasma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5283926A JPS5283926A (en) | 1977-07-13 |
| JPS6033089B2 true JPS6033089B2 (en) | 1985-08-01 |
Family
ID=5964580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP51150986A Expired JPS6033089B2 (en) | 1975-12-17 | 1976-12-17 | Method for separating precipitated proteins from albumin-containing suspensions |
Country Status (22)
| Country | Link |
|---|---|
| JP (1) | JPS6033089B2 (en) |
| AT (1) | AT346491B (en) |
| AU (1) | AU508955B2 (en) |
| BE (1) | BE849464R (en) |
| CA (1) | CA1079269A (en) |
| CH (1) | CH632277A5 (en) |
| DD (1) | DD128726A6 (en) |
| DE (1) | DE2556733C3 (en) |
| DK (1) | DK149135C (en) |
| EG (1) | EG12610A (en) |
| ES (1) | ES454379A2 (en) |
| FI (1) | FI56844C (en) |
| FR (1) | FR2335521A2 (en) |
| GB (1) | GB1569168A (en) |
| HU (1) | HU181926B (en) |
| IE (1) | IE44048B1 (en) |
| IL (1) | IL51110A (en) |
| MX (1) | MX3915E (en) |
| NL (1) | NL7613906A (en) |
| PL (1) | PL106430B3 (en) |
| SE (1) | SE445517B (en) |
| ZA (1) | ZA767503B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4483807A (en) * | 1981-01-27 | 1984-11-20 | Japan Atomic Energy Research Institute | Process for producing a slow release composite |
| DE3307871C2 (en) * | 1983-03-05 | 1986-10-30 | R & Z Biologicals S.A. (Pty.) Ltd., Cape Town | Process for obtaining high purity albumin |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2705230A (en) * | 1949-09-23 | 1955-03-29 | Allen F Reid | Method of purifying albumin |
| US2765299A (en) * | 1952-06-27 | 1956-10-02 | Armour & Co | Recovery of serum albumin |
| FR2247471A1 (en) * | 1973-10-15 | 1975-05-09 | Ts Institu | Pure serum albumin isolated from biological liquids - by treatment with alcohol and aliphatic carboxylic acid salt |
| DE2415079C3 (en) * | 1974-03-28 | 1980-02-14 | Plasmesco Ag, Zug (Schweiz) | Method for isolating albumin from blood plasma |
-
1975
- 1975-12-17 DE DE2556733A patent/DE2556733C3/en not_active Expired
-
1976
- 1976-12-10 IE IE2712/76A patent/IE44048B1/en unknown
- 1976-12-13 SE SE7613968A patent/SE445517B/en unknown
- 1976-12-14 DK DK559876A patent/DK149135C/en not_active IP Right Cessation
- 1976-12-15 GB GB52438/76A patent/GB1569168A/en not_active Expired
- 1976-12-15 IL IL51110A patent/IL51110A/en unknown
- 1976-12-15 EG EG769/76A patent/EG12610A/en active
- 1976-12-15 DD DD7600196377A patent/DD128726A6/en unknown
- 1976-12-15 FI FI763610A patent/FI56844C/en not_active IP Right Cessation
- 1976-12-15 NL NL7613906A patent/NL7613906A/en not_active Application Discontinuation
- 1976-12-16 FR FR7637897A patent/FR2335521A2/en active Granted
- 1976-12-16 HU HU76PA1271A patent/HU181926B/en unknown
- 1976-12-16 PL PL1976194451A patent/PL106430B3/en unknown
- 1976-12-16 CA CA268,010A patent/CA1079269A/en not_active Expired
- 1976-12-16 AU AU20599/76A patent/AU508955B2/en not_active Expired
- 1976-12-16 BE BE173309A patent/BE849464R/en not_active IP Right Cessation
- 1976-12-16 AT AT932976A patent/AT346491B/en not_active IP Right Cessation
- 1976-12-17 ES ES454379A patent/ES454379A2/en not_active Expired
- 1976-12-17 JP JP51150986A patent/JPS6033089B2/en not_active Expired
- 1976-12-17 CH CH1593176A patent/CH632277A5/en not_active IP Right Cessation
- 1976-12-17 MX MX76100452U patent/MX3915E/en unknown
- 1976-12-17 ZA ZA767503A patent/ZA767503B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BE849464R (en) | 1977-04-15 |
| AT346491B (en) | 1978-11-10 |
| SE7613968L (en) | 1977-06-18 |
| ZA767503B (en) | 1977-11-30 |
| AU2059976A (en) | 1978-06-22 |
| IL51110A (en) | 1979-11-30 |
| PL106430B3 (en) | 1979-12-31 |
| HU181926B (en) | 1983-11-28 |
| GB1569168A (en) | 1980-06-11 |
| FI56844B (en) | 1979-12-31 |
| DD128726A6 (en) | 1977-12-07 |
| FI763610A7 (en) | 1977-06-18 |
| DK559876A (en) | 1977-06-18 |
| IL51110A0 (en) | 1977-02-28 |
| DE2556733C3 (en) | 1986-10-02 |
| EG12610A (en) | 1979-06-30 |
| DE2556733B2 (en) | 1981-05-14 |
| ES454379A2 (en) | 1978-07-16 |
| AU508955B2 (en) | 1980-04-17 |
| CA1079269A (en) | 1980-06-10 |
| IE44048L (en) | 1977-06-17 |
| IE44048B1 (en) | 1981-07-29 |
| CH632277A5 (en) | 1982-09-30 |
| ATA932976A (en) | 1978-03-15 |
| FR2335521A2 (en) | 1977-07-15 |
| FR2335521B2 (en) | 1982-10-29 |
| FI56844C (en) | 1980-04-10 |
| JPS5283926A (en) | 1977-07-13 |
| MX3915E (en) | 1981-09-18 |
| SE445517B (en) | 1986-06-30 |
| DK149135C (en) | 1986-07-14 |
| NL7613906A (en) | 1977-06-21 |
| DK149135B (en) | 1986-02-10 |
| DE2556733A1 (en) | 1977-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4156681A (en) | Process for isolating albumin from blood | |
| EP1991063B1 (en) | Clarification of transgenic milk using depth filtration | |
| CN104672328B (en) | A kind of production method of Human Antithrombin Ⅲ | |
| CN103333240B (en) | Method for reclaiming human albumin from component IV precipitate | |
| CN101972479A (en) | Preparation process of intravenous injection human immunoglobulin | |
| JP2000506843A (en) | Filtration of plasma mixtures using cellulosic filter aids | |
| CN109651502B (en) | Method for simultaneously separating and purifying blood coagulation factors IX, X and VII from human plasma | |
| CN106676089A (en) | Method for preparing human prothrombin complex from plasma | |
| CN110066762A (en) | The method of industrialized production new born bovine purified blood serum | |
| CA1079269A (en) | Process of separating precipitated proteins from albumin - containing suspensions | |
| CN109836346A (en) | A kind of purifying technique of isoleucine fermentation liquid | |
| US20030077265A1 (en) | Isolation and purification of proteinase inhibitor ll | |
| CN117143222A (en) | Bovine serum albumin production method | |
| JPS6012015B2 (en) | How to filter soy sauce | |
| CN1463987A (en) | Process for extracting aloinose | |
| Schneider et al. | Technical improvements in heat-ethanol isolation of serum albumin | |
| CN114573687B (en) | Storage method of human antithrombin III intermediate product | |
| JPH01157347A (en) | Production of undenatured and sterile honey | |
| KR820002225B1 (en) | Process for obtaining hepatitis b surface antigen | |
| JPH07133290A (en) | New method for removing nucleic acid | |
| AU710566B2 (en) | Filtration of plasma mixtures using cellulose-based filter aids | |
| CN121064314A (en) | Pichia pastoris fermentation expression recombinant VII type humanized collagen purification production method | |
| JP3536989B2 (en) | Liquid food clarification method | |
| JPH0113355B2 (en) | ||
| JPH01296948A (en) | Purification of honey and purified honey |